Biotechnology company Leap Therapeutics Inc (NASDAQ: LPTX) announced on Monday that it has completed patient enrollment in Part B of its DeFianCe study, which is evaluating DKN-01 in combination with bevacizumab and chemotherapy as a second-line treatment for advanced colorectal cancer (CRC). The randomised, controlled Phase 2 study enrolled 188 patients, expanding from an initial target of 130 patients.
The primary endpoint of the study is progression-free survival (PFS), with an additional focus on PFS in patients with left-sided CRC. Secondary endpoints include objective response rate, duration of response and overall survival.
DKN-01, an anti-Dickkopf-1 (DKK1) antibody, is Leap's leading candidate and is being developed for esophagogastric, gynecologic and colorectal cancers.
The results of this study could provide crucial insights into the potential of DKN-01 to improve outcomes for CRC patients, particularly those receiving standard treatments.
Medivir partners with Eisai to evaluate fostrox in liver cancer
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Cytoki Pharma doses first patient with CK-0045 in Phase two proof-of-concept trial
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Alchemy partners with PatchRx to improve HIV medication adherence
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
HUTCHMED receives milestone payment from Takeda for FRUZAQLA sales
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
UZ Leuven chooses Sectra for enhanced cancer diagnostics
Biond Biologics signs clinical trial collaboration and supply agreement with Merck KGaA
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI